Facchinetti Fabio, Paganelli Simone, Comitini Giuseppina, Dante Giulia, Volpe Annibale
Unit of Obstetrics, Mother-Infant Department, University of Modena and Reggio Emilia, Reggio Emilia, Italy.
Am J Obstet Gynecol. 2007 May;196(5):453.e1-4; discussion 421. doi: 10.1016/j.ajog.2006.09.009.
The purpose of this study was to evaluate whether 17-alpha-hydroxyprogesterone caproate (17P) treatment affect changes in cervical length.
Women with singleton pregnancy, between 25 and 33 + 6 weeks of gestation, who were hospitalized for preterm labor were included. Patients with rupture of membranes and/or signs of chorioamnionitis were excluded. Sixty undelivered patients were allocated randomly to either observation or to receive 341 mg of 17P intramuscularly, twice each week until gestational week 36. Cervical length was measured by transvaginal ultrasound scanning at discharge and at day 7 and 21 after discharge. Statistical comparisons were done with analysis of variance and chi-square test.
Shortening of the cervix in the observation group (30 cases) was higher than in the 17P group (30 cases) both at day 7 (2.37 +/- 2.0 mm vs 0.83 +/- 1.74 mm; P = .002) and day 21 (4.60 +/- 2.73 mm vs 2.40 +/- 2.46 mm; P = .002). Treatment with 17P was associated with both a reduction in the risk of cervical shortening of > or = 4 mm (odds ratio, 0.18; 95% CI, 0.04-0.66) and in the risk of preterm delivery (odds ratio, 0.15; 95% CI, 0.04-0.58).
Undelivered patients after preterm labor undergo progressive shortening of the cervix, which is attenuated by 17P treatment.
本研究旨在评估己酸17-α-羟孕酮(17P)治疗是否会影响宫颈长度的变化。
纳入妊娠25至33 + 6周、因早产住院的单胎妊娠女性。排除有胎膜破裂和/或绒毛膜羊膜炎体征的患者。60例未分娩患者被随机分为观察组或接受每周两次、每次341 mg 17P肌肉注射,直至孕36周。出院时以及出院后第7天和第21天通过经阴道超声扫描测量宫颈长度。采用方差分析和卡方检验进行统计学比较。
观察组(30例)宫颈缩短情况在第7天(2.37±2.0 mm对0.83±1.74 mm;P = 0.002)和第21天(4.60±2.73 mm对2.40±2.46 mm;P = 0.002)均高于17P组(30例)。17P治疗与宫颈缩短≥4 mm风险降低(比值比,0.18;95%可信区间,0.04 - 0.66)以及早产风险降低(比值比,0.15;95%可信区间,0.04 - 0.58)相关。
早产未分娩患者的宫颈会逐渐缩短,17P治疗可使其缩短减缓。